Pinnacle Associates Ltd. Has $12.73 Million Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Pinnacle Associates Ltd. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 191,669 shares of the biotechnology company’s stock after selling 11,645 shares during the period. Pinnacle Associates Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $12,725,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of ARWR. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. First Horizon Corp purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at about $32,000. WPG Advisers LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 431 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 2.3%

Shares of ARWR opened at $79.69 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $11.23 billion, a price-to-earnings ratio of -37.06 and a beta of 1.28. The stock has a fifty day moving average price of $65.71 and a two-hundred day moving average price of $61.75. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $14.30 and a 52-week high of $82.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.75 earnings per share. Analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.97 EPS for the current fiscal year.

Analyst Ratings Changes

ARWR has been the topic of a number of research reports. B. Riley Financial upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. JPMorgan Chase & Co. began coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.80.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Arrowhead Pharmaceuticals and maintained a $100 price target, while also raising some medium- and longer-term earnings forecasts, including FY2026 and Q4 2026 estimates. Arrowhead Pharmaceuticals analyst estimate updates
• Positive Sentiment: Sanford C. Bernstein raised its price target from $35 to $46, signaling improved confidence in Arrowhead’s outlook, even though its rating remains Market Perform. Bernstein raises Arrowhead price target
• Neutral Sentiment: HC Wainwright made only small revisions to several quarterly EPS estimates, with some quarters slightly lower and others slightly higher, suggesting no major change in the overall thesis for Arrowhead’s pipeline-driven earnings path. HC Wainwright estimate revisions
• Neutral Sentiment: Recent coverage also highlighted Arrowhead’s ongoing valuation debate and upcoming clinical readouts, which may be keeping investor interest elevated ahead of key catalysts. Multiple important clinical readouts in 2H26
• Negative Sentiment: HC Wainwright trimmed several near-term earnings forecasts for Arrowhead, including Q3 2026, Q1 2027 and Q2 2027, which reflects expectations for continued losses before eventual improvement. Arrowhead near-term earnings estimate cuts

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares in the company, valued at $11,623,271.75. This trade represents a 7.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 36,065 shares of company stock valued at $2,554,562. 3.60% of the stock is currently owned by company insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.